215 related articles for article (PubMed ID: 11332076)
1. Transforming growth factor-beta pathway in human renal cell carcinoma and surrounding normal-appearing renal parenchyma.
Cardillo MR; Lazzereschi D; Gandini O; Di Silverio F; Colletta G
Anal Quant Cytol Histol; 2001 Apr; 23(2):109-17. PubMed ID: 11332076
[TBL] [Abstract][Full Text] [Related]
2. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.
Wang D; Kanuma T; Mizunuma H; Takama F; Ibuki Y; Wake N; Mogi A; Shitara Y; Takenoshita S
Cancer Res; 2000 Aug; 60(16):4507-12. PubMed ID: 10969799
[TBL] [Abstract][Full Text] [Related]
3. Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2.
Muro-Cacho CA; Rosario-Ortiz K; Livingston S; Muñoz-Antonia T
Clin Cancer Res; 2001 Jun; 7(6):1618-26. PubMed ID: 11410498
[TBL] [Abstract][Full Text] [Related]
4. TGF-beta signaling is disrupted in endometrioid-type endometrial carcinomas.
Piestrzeniewicz-Ulanska D; Brys M; Semczuk A; Rechberger T; Jakowicki JA; Krajewska WM
Gynecol Oncol; 2004 Oct; 95(1):173-80. PubMed ID: 15385128
[TBL] [Abstract][Full Text] [Related]
5. Reduction of transforming growth factor-beta type II receptor is caused by the enhanced ubiquitin-dependent degradation in human renal cell carcinoma.
Fukasawa H; Yamamoto T; Fujigaki Y; Misaki T; Ohashi N; Takayama T; Suzuki S; Mugiya S; Oda T; Uchida C; Kitagawa K; Hattori T; Hayashi H; Ozono S; Kitagawa M; Hishida A
Int J Cancer; 2010 Oct; 127(7):1517-25. PubMed ID: 20073064
[TBL] [Abstract][Full Text] [Related]
6. Activation of the TGF-beta/Smad signaling pathway in focal segmental glomerulosclerosis.
Kim JH; Kim BK; Moon KC; Hong HK; Lee HS
Kidney Int; 2003 Nov; 64(5):1715-21. PubMed ID: 14531804
[TBL] [Abstract][Full Text] [Related]
7. Systematic analysis of the TGF-beta/Smad signalling pathway in the rhabdomyosarcoma cell line RD.
Wang H; Yang GH; Bu H; Zhou Q; Guo LX; Wang SL; Ye L
Int J Exp Pathol; 2003 Jun; 84(3):153-63. PubMed ID: 12974945
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-beta type II receptors and smad proteins in follicular thyroid tumors.
West J; Munoz-Antonia T; Johnson JG; Klotch D; Muro-Cacho CA
Laryngoscope; 2000 Aug; 110(8):1323-7. PubMed ID: 10942134
[TBL] [Abstract][Full Text] [Related]
9. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells.
Poncelet AC; de Caestecker MP; Schnaper HW
Kidney Int; 1999 Oct; 56(4):1354-65. PubMed ID: 10504488
[TBL] [Abstract][Full Text] [Related]
10. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Kang Y; Prentice MA; Mariano JM; Davarya S; Linnoila RI; Moody TW; Wakefield LM; Jakowlew SB
Exp Lung Res; 2000 Dec; 26(8):685-707. PubMed ID: 11195465
[TBL] [Abstract][Full Text] [Related]
12. Enhanced TGF-beta/Smad signaling in the early stage of diabetic nephropathy is independent of the AT1a receptor.
Okazaki Y; Yamasaki Y; Uchida HA; Okamoto K; Satoh M; Maruyama K; Maeshima Y; Sugiyama H; Sugaya T; Kashihara N; Makino H
Clin Exp Nephrol; 2007 Mar; 11(1):77-87. PubMed ID: 17385003
[TBL] [Abstract][Full Text] [Related]
13. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition.
Yang J; Dai C; Liu Y
J Am Soc Nephrol; 2005 Jan; 16(1):68-78. PubMed ID: 15537870
[TBL] [Abstract][Full Text] [Related]
14. Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis.
Han G; Lu SL; Li AG; He W; Corless CL; Kulesz-Martin M; Wang XJ
J Clin Invest; 2005 Jul; 115(7):1714-23. PubMed ID: 15937546
[TBL] [Abstract][Full Text] [Related]
15. Parenchymal transforming growth factor beta-1: its type II receptor and Smad signaling pathway correlate with inflammation and fibrosis in chronic liver disease of viral etiology.
Calabrese F; Valente M; Giacometti C; Pettenazzo E; Benvegnu L; Alberti A; Gatta A; Pontisso P
J Gastroenterol Hepatol; 2003 Nov; 18(11):1302-8. PubMed ID: 14535988
[TBL] [Abstract][Full Text] [Related]
16. Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines.
Hu W; Wu W; Nash MA; Freedman RS; Kavanagh JJ; Verschraegen CF
Anticancer Res; 2000; 20(2A):729-33. PubMed ID: 10810347
[TBL] [Abstract][Full Text] [Related]
17. Sequential gonadotropin treatment of immature mice leads to amplification of transforming growth factor beta action, via upregulation of receptor-type 1, Smad 2 and 4, and downregulation of Smad 6.
Guéripel X; Benahmed M; Gougeon A
Biol Reprod; 2004 Mar; 70(3):640-8. PubMed ID: 14585817
[TBL] [Abstract][Full Text] [Related]
18. IGF-I and IGFBP-3 augment transforming growth factor-beta actions in human renal carcinoma cells.
Rosendahl AH; Forsberg G
Kidney Int; 2006 Nov; 70(9):1584-90. PubMed ID: 16969385
[TBL] [Abstract][Full Text] [Related]
19. Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: resistance mechanism to transforming growth factor-beta.
Park YN; Chae KJ; Oh BK; Choi J; Choi KS; Park C
Hepatogastroenterology; 2004; 51(56):396-400. PubMed ID: 15086168
[TBL] [Abstract][Full Text] [Related]
20. Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.
Cooper SJ; Zou H; Legrand SN; Marlow LA; von Roemeling CA; Radisky DC; Wu KJ; Hempel N; Margulis V; Tun HW; Blobe GC; Wood CG; Copland JA
Oncogene; 2010 May; 29(20):2905-15. PubMed ID: 20208565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
